Recent advances in atherothrombotic diseases;Recenti progressi in tema di aterotrombosi

Recenti Progressi in Medicina

Volumn 97, Issue 4, 2006, Pages 183-188

  Andreotti, Felicita ^a   Lavorgna, Alberto ^a   Coluzzi, Giulio ^a   Marzo, Francesca ^a   Cecchetti, Silvia ^a   Conti, Elena ^b   Becker, Richard C ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c DUKE UNIVERSITY   (United States)

Author keywords

Arterial trombosis; Atherosclerosis; Growth factors; Inherited and acquired thrombophilias; Progenitor cells

Indexed keywords

ERYTHROPOIETIN; GROWTH FACTOR; SOMATOMEDIN C;

ANAMNESIS; ANTIPHOSPHOLIPID SYNDROME; ARTERIOGRAPHY; ARTERY OCCLUSION; ARTERY THROMBOSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DEMOGRAPHY; DNA POLYMORPHISM; HEMOSTASIS; HUMAN; MUSCLE REGENERATION; MYELOPROLIFERATIVE DISORDER; PREVALENCE; REVIEW; STEM CELL MOBILIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; VASCULAR SURGERY;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CORONARY THROMBOSIS; ERYTHROPOIETIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACRANIAL THROMBOSIS; NITRIC OXIDE; RISK FACTORS; STEM CELLS; THROMBOPHILIA;

EID: 33646530543     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Fuster V, Goldman L, Bennett JC. Atherosclerosis, thrombosis and vascular biology. In: Cecil's Textbook of Medicine. Philadelphia: Saunders 2001: 317-22.
2. Andreotti F, Becker RC. Atherothrombotic disorders: new insights from hematology. Circulation 2005; 111: 1855-63.
3. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004; 110: 2260-5.
4. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
5. Szmitko PE, Fedak PWM, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 2003; 107: 3093-100.
6. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
7. Andreotti F, Crea F, Conti E. Heart-kidney interactions in ischemic syndromes. Circulation 2004; 109: e31-e32.
8. Andreotti F, Testa L, Biondi-Zoccai G, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25307 patients Eur Heart J 2006; 27: 519-26.
9. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-4.
10. Nowak-Gottl U, Strater R, Heinecke A. Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischaemic stroke in childhood. Blood 1999; 94: 3678-82.
11. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
12. Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000; 36: 717-22.
13. Boekholdt SM, Bijsterveld NR, Moons AG, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104: 3063-8.
14. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG. Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 2003; 101: 3037-41.
15. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-57.
16. Burzotta F, Paciaroni K, De Stefano V, et al. G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12034 subjects. Heart 2004; 90: 82-6.
17. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
18. Burzotta F, Paciaroni K, De Stefano V, et al. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 2002; 23: 26-30.
19. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
20. French JK, Van de Water NS, Sutton TM, et al. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. Am Heart J 2003; 145: 118-24.
21. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
22. Mackworth-Young CG, Andreotti F, Harmer I, et al. Endothelium-derived haemostatic factors and the antiphospholipid syndrome. Br J Rheumatol 1995; 34: 201-6.
23. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Haematol 1995; 203-22.
24. Schafer AI. Current concepts: thrombocytosis. N Engl J Med 2004; 350: 1212-9.